The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)

Age Related Macular Degeneration Clinical Trial

Official title:

The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02438111
• Other study ID #: KEK BE 205/13, PB_2016-01922
• Status: Active, not recruiting
• Start date: December 2013
• Est. completion date: December 2023

Study information

• Verified date: April 2023
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of this study is to assess whether compositional and functional alterations of the gut metagenome may be related to AMD. The primary variable for this assessment is the composition of the gut metagenome which will be analyzed by shotgun sequencing to characterize the faecal metagenome. The secondary endpoint is to assess whether single nucleotide polymorphisms in CFH, ARMS2, C3, PLEKHA1, HTRA-1, VEGF-A, VEGF-B, VEGFR and APOE genes which have been shown to be risk factors for the development of AMD and other macular diseases correlate with alterations in the gut metagenome .

Description:

Age-related macular degeneration (AMD) is the most frequent cause of blindness in the elderly. Despite major research efforts in the last decades the etiology of AMD remains largely undefined and therefore treatment options are only very limited. However, there is evidence that nutrition and inflammation play a role in the pathogenesis of AMD . The latter is also corroborated by the finding that single nucleotide polymorphism in the gene encoding complement factor H is associated with AMD . In addition to CHF other genes such as ARMS2, C3, PLEKHA1, HTRA-1, VEGF-A, VEGF-B, VEGFR and APOE have been associated with development of AMD. Recent findings have implicated the gut microbiota as a contributor of metabolic diseases through the modulation of host metabolism and inflammation . Gut bacteria use mostly fermentation to generate energy, converting sugars, in part, to short-chain fatty acid, that are used by the host as energy source. Beyond short-chain fatty acids gut bacteria can provide some amino acids and contribute certain vitamins such as biotin to the host . The investigators propose to investigate whether compositional and functional alterations of the gut microbiota are a risk factor for developing AMD.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1200
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Subject must be willing to give written informed consent and willing to provide blood and stool probes

• Patients with clinically confirmed AMD 18 years of age or greater

• Probands with no signs of AMD 18 years of age or greater

Exclusion criteria:

• Smoking

• Chronic inflammatory disease (autoimmune diseases such as rheumatoid arthritis, lupus erythematodes, chronic inflammatory bowel disease)

• Diabetes as defined by The World Health Organization (WHO) criteria

• Treated hyperlipidemia

• Obesity with a body mass index (BMI) greater than or equal to 30

• Recent (3 month) history of use of systemic antibiotics

• Opacities of ocular media excluding detailed observation of the retina

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• Macular Degeneration

Intervention

Genetic:
• metagenome
metagenome

Locations

Country	Name	City	State
Switzerland	Inselspital Bern, Department of Ophthalmology	Bern

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	taxonomic and functional characterization of gut microbiota		3 years
Secondary	Gut-microbiota-based AMD classification		3 years
Secondary	AMD-associated gut microbial markers		3 years